Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy
about
Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapyIL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery.A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infectionDevelopment of immunotherapeutic strategies for HIV-1.Detection and quantification of HIV-1 specific CD4 helper and CD8 cytotoxic cells: their role in HIV-1-infected individuals and vaccine recipients.Candidate vaccines for immunotherapy in HIV.Prospects for immune reconstitution in HIV-1 infection.Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up.Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune ActivationRates of postoperative complications among human immunodeficiency virus-infected women who have undergone obstetric and gynecologic surgical procedures.Thymic activity in late-stage HIV-1 infected individuals receiving highly active antiretroviral therapy: potential effect of steroid therapy.Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection.
P2860
Q24815428-5A271BC3-2393-4913-976F-42386FFCB560Q34112781-1C60FD3A-4E3C-416E-A43C-CC854EC05A8CQ34344555-0B47F67D-E9F8-4E53-B5D4-FEA8D4D335BCQ34452629-9E8CEC95-03A8-4921-B8BC-E2D72AE1A321Q34459401-B666E224-F6A9-4271-9C7D-229D8659BD64Q34459435-9C490C8E-D7C5-48B5-81B4-FCA14A11E82CQ34609562-3946ACE7-3985-4329-8E13-0B180B937636Q37037090-CC0DC2D7-2CBB-4CCD-8395-4173990BFCFFQ38086432-B86E634D-1B4B-42C5-BAD3-0D7BEB5DB9D7Q41665214-8DEB669D-4758-4152-8330-47080C2030E9Q43465036-5A20B911-5EF2-42CE-966A-10128A3898B3Q44024385-84AEBFE2-46E6-463E-8222-3272CDC11953Q45723089-21B162F2-1A03-4ADA-9818-282851997E99Q50899394-D47D36EA-53F0-4F26-95E2-64B8937D5148Q53653066-3CB4668F-F6D4-4C0C-A32D-5BB3EA86B97F
P2860
Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy
description
article
@en
im Oktober 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 1999
@uk
name
Induction of HIV-1-specific T ...... active anti-retroviral therapy
@en
Induction of HIV-1-specific T ...... active anti-retroviral therapy
@nl
type
label
Induction of HIV-1-specific T ...... active anti-retroviral therapy
@en
Induction of HIV-1-specific T ...... active anti-retroviral therapy
@nl
prefLabel
Induction of HIV-1-specific T ...... active anti-retroviral therapy
@en
Induction of HIV-1-specific T ...... active anti-retroviral therapy
@nl
P2093
P2860
P1476
Induction of HIV-1-specific T ...... active anti-retroviral therapy
@en
P2093
C Antonopoulos
M R Nelson
S Morris-Jones
P2860
P356
10.1046/J.1365-2249.1999.01012.X
P407
P577
1999-10-01T00:00:00Z